In addition to the novelty of high-throughput drug combination screening against multiple MPNST models, this study is also the most comprehensive to explore the genotype-phenotype association between NF1 loss, the primary oncogenic driver of MPNST, and the quantifiable response to relevant chemotherapeutic agents. The gene discussed is NF1; the disease is malignant peripheral nerve sheath tumor.